- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07949045
Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology (EPIDOCAVILH)
Pilot Study for the Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology
In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.
Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.
In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: STEPHANIE NOEL
- Номер телефона: 0033549443083
- Электронная почта: stephanie.noel@chu-poitiers.fr
Учебное резервное копирование контактов
- Имя: MAUD BRECHET
- Номер телефона: 0033549029991
- Электронная почта: MAUD.BRECHET@chu-poitiers.fr
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Patient ≥ 18 years old.
- Consultation for treatment initiation (first-line or relapse) for gynecological, digestive, urological, or hematological cancer.
- Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
- Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
- Patient declaring having a general practitioner.
- Patient's general practitioner agreeing to participate in the study.
- Patient covered by the French social Security system or through a third party.
Non-Inclusion Criteria:
- Patient already receiving care for this pain from the reference pain center or supportive care team.
- Patient unable to understand, write, or speak French.
- Patient diagnosed with uncontrolled psychiatric disorders.
- Patient with chronic pain unrelated to cancer.
- Pain related to therapeutic procedures.
- Patient residing in a medicalized facility.
- Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
- Patient with a significant impairment of general condition (ECOG-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Исследования в области здравоохранения
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Early management of acute pain
Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP. Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary. Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms. |
Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study). |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Proportion of eligible patients that provide a consent to participate
Временное ограничение: 1 day
|
Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent. |
1 day
|
|
Proportion of general pactitioner that confirmed their participation
Временное ограничение: 2 days
|
General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation. |
2 days
|
|
Proportion of consultations with the general practitioner performed
Временное ограничение: 28 days
|
Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed. |
28 days
|
|
Proportion of consultations at the hospital performed
Временное ограничение: 28 days
|
Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed. |
28 days
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in pain severity after 28 days
Временное ограничение: 28 days
|
Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain). |
28 days
|
|
Change in pain interference after 28 days
Временное ограничение: 28 days
|
Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain). |
28 days
|
|
Change in quality of life after 28 days
Временное ограничение: 28 days
|
Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life). |
28 days
|
|
Proportion of patients requiring a specific pain management
Временное ограничение: 28 days
|
Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team. |
28 days
|
|
Global satisfaction of the patients
Временное ограничение: 28 days
|
Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied") |
28 days
|
|
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
Временное ограничение: 28 days
|
The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch |
28 days
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Неврологические проявления
- Заболевания нервной системы
- Урогенитальные новообразования
- Новообразования по локализации
- Мужские мочеполовые заболевания
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Желудочно-кишечные заболевания
- Нейроповеденческие проявления
- Расстройства восприятия
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Новообразования
- Желудочно-кишечные новообразования
- Урологические новообразования
- Агнозия
- Качество, доступ и оценка здравоохранения
- Следственные методы
- Эпидемиологические методы
- Терапия
- Сбор данных
- Механизмы оценки здравоохранения
- Качество здравоохранения
- Общественное здравоохранение
- Окружающая среда и общественное здравоохранение
- Контроль поведения
- Иммобилизация
- Обследования и анкеты
- Сдержанность, физическая
Другие идентификационные номера исследования
- EPIDOCAVILH
- 2026-A01683-48 (Другой идентификатор: French Ethics Committee Number (ID-RCB))
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .